Trevi Therapeutics, Inc. (TRVI)
TRVI Stock Price Chart
Explore Trevi Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze TRVI price movements and trends.
TRVI Company Profile
Discover essential business fundamentals and corporate details for Trevi Therapeutics, Inc. (TRVI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 May 2019
Employees
31.00
CEO
Jennifer L. Good
Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
TRVI Financial Timeline
Browse a chronological timeline of Trevi Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.10.
Earnings released on 7 Aug 2025
EPS came in at -$0.09 surpassing the estimated -$0.10 by +10.00%.
Earnings released on 8 May 2025
EPS came in at -$0.09 surpassing the estimated -$0.13 by +30.77%.
Earnings released on 18 Mar 2025
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%.
Earnings released on 6 Nov 2024
EPS came in at -$0.13 falling short of the estimated -$0.12 by -8.33%.
Earnings released on 8 Aug 2024
EPS came in at -$0.12 falling short of the estimated -$0.11 by -9.09%.
Earnings released on 7 May 2024
EPS came in at -$0.11 falling short of the estimated -$0.09 by -22.22%.
Earnings released on 20 Mar 2024
EPS came in at -$0.08 surpassing the estimated -$0.10 by +20.00%, while revenue for the quarter reached $176.00K .
Earnings released on 9 Nov 2023
EPS came in at -$0.08 surpassing the estimated -$0.09 by +11.11%.
Earnings released on 10 Aug 2023
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%.
Earnings released on 11 May 2023
EPS came in at -$0.06 surpassing the estimated -$0.08 by +25.00%.
Earnings released on 16 Mar 2023
EPS came in at -$0.06 surpassing the estimated -$0.11 by +45.45%.
Earnings released on 10 Nov 2022
EPS came in at -$0.12 surpassing the estimated -$0.15 by +20.00%.
Earnings released on 11 Aug 2022
EPS came in at -$0.14 surpassing the estimated -$0.21 by +33.33%.
Earnings released on 12 May 2022
EPS came in at -$0.24 surpassing the estimated -$0.31 by +22.58%.
Earnings released on 17 Mar 2022
EPS came in at -$0.28 surpassing the estimated -$0.34 by +17.65%.
Earnings released on 10 Nov 2021
EPS came in at -$0.34 falling short of the estimated -$0.33 by -3.03%.
Earnings released on 12 Aug 2021
EPS came in at -$0.49 falling short of the estimated -$0.46 by -6.52%.
Earnings released on 13 May 2021
EPS came in at -$0.43 surpassing the estimated -$0.49 by +12.24%.
Earnings released on 25 Mar 2021
EPS came in at -$0.52 falling short of the estimated -$0.45 by -15.56%.
Earnings released on 12 Nov 2020
EPS came in at -$0.41 surpassing the estimated -$0.59 by +30.51%.
TRVI Stock Performance
Access detailed TRVI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.